BIOMED   24552
INSTITUTO DE INVESTIGACIONES BIOMEDICAS
Unidad Ejecutora - UE
congresos y reuniones científicas
Título:
Histamine modulates tumor growth and antitumor immunity in 4T1 triple negative breast cancer developed in H4R knock-out (H4R KO) and wild-type (WT) BALB/c mice.
Autor/es:
HELENA STERLE; MELISA NICOUD; DIEGO MARTINEL LAMAS; JUAN C PERAZZO; GRACIELA CREMASCHI; VANINA MEDINA
Lugar:
Florencia
Reunión:
Congreso; European Histamine Research Society 45th Annual Meeting; 2016
Resumen:
It is well-known that histamine regulates cellular immune responses, affecting maturation and activity of lymphocytes and myeloid-derived suppressor cells, which are considered as potential effectors of antitumor immunity and may interfere with tumor progression. The aim of the present work was to investigate the influence of the lack of histamine H4 receptor (H4R) on the tumorigenic capacity, metastatic potential and antitumor immunity in response to histamine in a triple negative breast cancer (TNBC) model. Thus, we evaluated tumor growth parameters, the phenotype of splenic and intra-tumoral lymphocytes in syngeneic H4R knock-out (H4R KO) and wild-type (WT) mice, inoculated orthotopically with 4T1 murine TNBC cells. CD4+, CD8+, CD11b+, C19+, CD3+, NK1.1+ cells were quantified in the spleens and tumors by flow cytometry. Results indicate that histamine (0.1-10 µM) produced a 2-fold decrease in proliferation evaluated by BrdU-incorporation without inducing significant apoptosis in vitro in 4T1 TNBC cells. We observed non-significant differences in latency period or tumor growth between WT and KO mice while spleen weight was significantly higher in WT than in KO mice. Histamine (1 mg/kg.day s.c.) reduced tumor volume in KO mice (743 vs. 1045 mm3 after 15 days of treatment, *P